drugset
drugset / Trial / NCT00115999

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999 ↗

Phase 3 Completed 300 enrolled ARCA Biopharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.

Timeline

Start
2005-04
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alfimeprase Protein / enzyme biologic 0.3 mg/kg Other

Indications

arterial occlusion